Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas.

ABSTRACT:

Background

Diffuse intrinsic pontine gliomas (DIPGs) pose a significant challenge as a highly aggressive and currently incurable form of pediatric brain cancer, necessitating the development of novel therapeutic strategies. Omacetaxine, an FDA-approved protein synthesis inhibitor for treating certain hematological malignancies, was investigated for its potential antitumor effects against preclinical DIPG models.

Methods

We employed primary DIPG cultures to study omacetaxine's cytotoxicity and its impact on colony formation. Annexin V staining and flow cytometry assessed apoptosis. Wound healing assays evaluated migration, while western blotting determined inhibition of oncogenic proteins. We tested omacetaxine's therapeutic efficacy in an orthotopic DIPG model and assessed b

SUBMITTER: Chen Y 

PROVIDER: S-EPMC10976909 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature